科研之友
微信
新浪微博
Facebook
分享链接
摘要
New molecular and genetic tests are becoming more and more important in research and clinical practice. Using these tests to offer individualised therapy to patients with breast cancer is particularly important in the context of health economics. The targeted use of therapies increases their effectiveness and reduces follow-up costs by preventing recurrence andmetastatic disease. Avoiding over-treatment additionally reduces costs. Genetic tests are initially associated with higher costs but in the longer term they can reduce costs, as shown by health economic models and cost-effectiveness analyses.
- 出版日期2013-6
